Etid klinik pou Kansè ovè nan Indiana
23 etid pou Kansè ovè ap chèche patisipan nan sit nan Indiana.
Vil nan Indiana
Tèks ofisyèl etid la (Anglè)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- UChicago Medicine Northwest Indiana, Crown Point
- Woodland Cancer Care Center, Michigan City
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Oct 5, 2026 · NCT05564377A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- IU Simon Cancer Center, Indianapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Parkview Research Center /ID# 274338, Fort Wayne
- Indiana University Melvin and Bren Simon Cancer Center /ID# 275492, Indianapolis
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT06890338A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0284 - Community Cancer Center North, Indianapolis
- Site 0217 - St Vincent Hospital and Health Care Centers, Indianapolis
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05128825A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Indiana University (IU) School of Medicine, Indianapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Community Health Network, Indianapolis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Parkview Research Center at Parkview Regional Medical Center ( Site 0055), Fort Wayne
- Franciscan Health Indianapolis ( Site 0081), Indianapolis
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 17, 2026 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Parkview Research Center, Fort Wayne
Ap rekriteFaz 2
Laj 18 a 99 · Fanm · Mizajou Sep 15, 2026 · NCT07023627A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Parkview Research Center at Parkview Regional Medical Center ( Site 0003), Fort Wayne
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 3, 2026 · NCT06824467Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Aug 26, 2026 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
Ap rekriteFaz 1
Laj 15 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Riley Hospital for Children, Indianapolis
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
- Indiana University, Indianapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT07306559A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- IU Health North Hospital, Carmel
- UChicago Medicine Northwest Indiana, Crown Point
- Goshen Center for Cancer Care, Goshen
- ak 2 plis
Ap rekrite
Laj 35 a 50 · Fanm · Mizajou Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- IU Health North Hospital, Carmel
- Northwest Cancer Center - Crown Point, Crown Point
- UChicago Medicine Northwest Indiana, Crown Point
- ak 13 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Community Health Network, Indianapolis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT04657068A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Community Health Network - MD Anderson, Indianapolis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06161025A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- UChicago Medicine - Northwest Indiana, Crown Point
- Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
- Community Health Network, Inc, Indianapolis
- ak 3 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Indiana University, Indianapolis
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 2, 2026 · NCT06819007Integrated Cancer Repository for Cancer Research
- Parkview Research Center, Fort Wayne
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 1, 2026 · NCT05735080cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Floyd, New Albany
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.